In a report released yesterday, Omotayo Okusanya from Jefferies reiterated a Buy rating on Healthcare Trust (NYSE: HTA), with a price target of $30. The company’s shares closed yesterday at $26.61.
According to TipRanks.com, Okusanya is a 4-star analyst with an average return of 7.5% and a 60.8% success rate. Okusanya covers the Financial sector, focusing on stocks such as Easterly Government Properties, DCT Industrial Trust Inc, and Office Properties Trust.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Healthcare Trust with a $28.75 average price target, which is an 8.0% upside from current levels. In a report issued on July 3, BMO Capital also maintained a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.87 and a one-year low of $24.06. Currently, Healthcare Trust has an average volume of 1.7M.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Healthcare Trust of America, Inc. operates as an integrated, self-administered and self-managed real estate investment trust. It acquires, owns and operates medical office buildings and other facilities that serve the healthcare industry.
